The progress of pluripotent stem cell-derived pancreatic β-cells regeneration for diabetic therapy

Front Endocrinol (Lausanne). 2022 Jul 28:13:927324. doi: 10.3389/fendo.2022.927324. eCollection 2022.

Abstract

Diabetes is a complex metabolic disorder of carbohydrate metabolism, characterized by high blood glucose levels either due to an absolute deficiency of insulin secretion or an ineffective response of cells to insulin, a hormone synthetized by β-cells in the pancreas. Despite the current substantial progress of new drugs and strategies to prevent and treat diabetes, we do not understand precisely the exact cause of the failure and impairment of β-cells. Therefore, there is an urgent need to find new methods to restore β-cells. In recent years, pluripotent stem cells (PSCs) such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSC) can serve as an ideal alternative source for the pancreatic β-cells. In this review, we systematically summarize the current progress and protocols of generating pancreatic β-cells from human PSCs. Meanwhile, we also discuss some challenges and future perspectives of human PSCs treatments for diabetes.

Keywords: diabetes mellitus; embryonic stem cells; generation; human pluripotent stem cells; stem cells.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Differentiation
  • Diabetes Mellitus* / metabolism
  • Diabetes Mellitus* / therapy
  • Humans
  • Insulin-Secreting Cells* / metabolism
  • Pluripotent Stem Cells*
  • Regeneration